Post-Myocardial Infarction Free Rx Event and Economic Evaluation - MI FREEE


Adherence with evidence-based medications in patients with coronary artery disease is low. One of the most commonly implicated reasons is medication cost. The current trial sought to study if eliminating copayments for statins, beta-blockers and angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers (ACEI/ARBs) would be associated with improved clinical outcomes and reduced health care costs in patients with a recent myocardial infarction (MI).